Vol 70, No 6 (2020)
Research paper (original)
Published online: 2020-12-04

open access

Page views 701
Article views/downloads 645
Get Citation

Connect on Social Media

Connect on Social Media

Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland

Joanna Kufel-Grabowska12, Barbara Radecka34, Joanna Streb5, Agnieszka Jagiełło-Gruszfeld6, Joanna Hudała-Klecha4, Ewa Szombara6, Renata Sienkiewicz6, Bogumiła Czartoryska-Arłukowicz7, Piotr Witasik8, Katarzyna Sokołowska9, Wojciech Wysocki101112
Nowotwory. Journal of Oncology 2020;70(6):225-229.


Breast cancer is the most common cancer among women in Poland and worldwide; after lung cancer it is the second highest cause of death among females with malignancies. HER2 positive breast cancer occurs in ca.15–20% of all cases. More often than other subtypes, it affects younger patients and more often spreads metastasises to internal organs.

The new drugs against the HER2 receptor significantly improve patients’ prognoses, regardless of the initial stage. The authors of the study involved 1503 patients with HER2 positive breast cancer from all stages (I–IV); 482 patients received preoperative systemic therapy (chemotherapy or hormonal therapy), 385 trastuzumab. Among the 1219 females qualified to surgery, 734 (60%) underwent a mastectomy, 485 (40%) had breast conserving therapy with adjuvant radiotherapy, some of them had preoperative systemic treatment.

Article available in PDF format

View PDF Download PDF file


  1. Tao Z, Shi A, Lu C, et al. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2014; 72(2): 333–338.
  2. Cronin KA, Harlan LC, Dodd KW, et al. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9): 963–968.
  3. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17(6): 791–800.
  4. PTBR Sm, Mikułowska M, Komorowska A, Falkiewicz B. Gryglewicz J. Rak piersi w Polsce – leczenie to inwestycja. Sequence, Uczelnia Łazarskiego, Warszawa 2014.
  5. Tan MP. Is there an Ideal Breast Conservation Rate for the Treatment of Breast Cancer? Ann Surg Oncol. 2016; 23(9): 2825–2831.
  6. Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(10): 1674.
  7. Salindera S, Ogilvy M, Spillane A. What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand? Breast. 2020; 51: 94–101.
  8. Herman K, Śliwczyński A, Wysocki W. Wyniki, metody i koszty leczenia raka piersi w Polsce (w latach 2005–2007). Nowotwory. Journal of Oncology. 2014; 64(1): 33–39.
  9. Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast. 2011; 20(6): 485–490.
  10. Mamtani A, Morrow M. Why Are There So Many Mastectomies in the United States? Annu Rev Med. 2017; 68: 229–241.